There has been considerable research regarding how boosting Endocannabinoid System performance may improve health. One such study is The Endocannabinoid System as an Emerging Target of Pharmacotherapy by Dr. Pal Pacher published in 2006. Among Dr. Pacher’s conclusions was the following:
In the past decade, the endocannabinoid system has been implicated in a growing number of physiological functions, both in the central and peripheral nervous systems and in peripheral organs. Modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathological conditions, ranging from mood and anxiety disorders, movement disorders such as Parkinson’s and Huntington’s disease, neuropathic pain, multiple sclerosis and spinal cord injury, to cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity/metabolic syndrome, and osteoporosis, to name just a few.
Dr. Pacher then went on to provide a template of the potential health challenges that improved ECS performance could positively affect, as follows:
*Energy Metabolism: Appetite Regulation, Peripheral Energy Metabolism, Obesity and Metabolic Abnormalities, Cachexia and Anorexia
*Pain and Inflammation
*Central Nervous System Disorders: Neurotoxicity and Neuro-trauma; Stroke; Multiple Sclerosis and Spinal Cord Injury; Movement Disorders (Basal Ganglia Disorders – Parkinson’s Disease, Huntington’s Disease, Tourette’s Syndrome); Amyotrophic Lateral Sclerosis (ALS); Alzheimer’s; Epilepsy; Mental Disorders (Schizophrenia, Anxiety and Depression); Insomnia; Nausea and Emesis (Vomiting); Drug addiction and Alcohol Disorders (Opiates, Nicotine, Cocaine, Alcohol, Psychostimulants)
*Cardiovascular and Respiratory Disorders: Hypertension; Circulatory Shock (Hemorrhagic, Cardiogenic, Endotoxic); Myocardial Reperfusion Injury; Atherosclerosis; Asthma
*Eye Disorders (Glaucoma and RetinopathyCancer
*Gastrointestinal and Liver: Inflammatory Bowel Syndrome; Acute and Chronic Liver Disease (Hepatitis and Liver Cirrhosis)
*Musculoskeletal Disorders: Arthritis; Osteoporosis
*Reproduction
(PAL PACHER, SANDOR BATKAI, and GEORGE KUNOS Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, Pharmacol Rev. 2006 September ; 58(3): 389-462)
CBDs
ECS uses Endocannabinoids (those it manufactures) to signal CB1 and CB2 receptors. Fortunately nature has also provided us with an EXTERNAL source of Cannabinoids (most commonly referred to as CBDs). Research has shown the addition of external Cannabinoids signals the body to (both) manufacture more endocannabinoids and build more CB1 and CB2 receptors, which in turn, increases ECS efficiency as well as our baseline of Endocannabinoid activity.
As noted previously research has also shown the greatest therapeutic contributions result from Full-Spectrum Hemp Oil CBDs which contain ALL 110+ Cannabinoids – because the compounds work synergistically in a sum of the whole is greater than the sum of the parts way.
I am not an advocate of smoking because of the damage to lung tissue. Oral consumption will be a healthier option. I use and recommend this wonderful, pure CBD.
Path of Purity – Product Overview
Path of Purity is a 100% organic, non-GMO, proprietary formulation of full spectrum Phytocannabinoid Rich (PCR) CBD hemp oil in tablet form. PoP is Pesticide and Heavy Metal Free, as well as Gluten Free, Sugar Free, Dairy Free, and Vegan. Path of Purity is specifically bred and formulated for a superior therapeutic entourage effect. Each PoP tablet contains 50mg of PCR, is measured and metered and scientifically-engineered with a proprietary dual-tier-release delivering 25mg at a time for optimal bioavailability which is best-matched to the innate capabilities of our CB1 and CB2 Receptors to take in CBDs most efficiently. Path of Purity exceeds all Federal Regulations for Industrial Hemp including the content of THC which is less than .03%. Please note that while independent laboratory data confirms Limit of Quantitation (LOQ) requirements, PoP has not yet been formally studied for detection in drug testing.
